PAVS vs RKDA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
PAVS exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a catastrophic price collapse of 99.9% over the last year. While the company shows a low debt-to-equity ratio and a positive gross margin, these are overshadowed by a -54.84% profit margin and a total lack of institutional analyst coverage. The extreme revenue growth figure (18,033%) appears to be a mathematical anomaly from a near-zero base rather than sustainable scaling. Given the technical trend of 0/100 and the price drop from a 52-week high of $1680 to $1.67, the asset is currently a high-risk value trap.
RKDA exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all health metrics. Despite a strong current ratio of 3.09 suggesting short-term liquidity, the company suffers from severe operational inefficiency with an operating margin of -152.61% and declining year-over-year revenue growth of -25.90%. The catastrophic 5-year price decline of -98.8% and a 0/100 technical trend score confirm a persistent bearish trajectory. The stock is currently a classic value trap, trading at a low Price/Book (0.39) but lacking any catalyst for recovery.
Compare Another Pair
Related Comparisons
PAVS vs RKDA: Head-to-Head Comparison
This page compares Paranovus Entertainment Technology Ltd. (PAVS) and Arcadia Biosciences, Inc. (RKDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.